Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate, buloxibutid, for the treatment of idiopathic pulmonary fibrosis (IPF).
Buloxibutid, a first-in-class AT2 receptor agonist, has the potential to modify the disease progression of IPF by promoting alveolar repair and resolving fibrosis.
Fast Track designation aims to expedite the development of drugs for serious or life-threatening conditions. Vicore plans to leverage this designation to expedite the development and potential approval of buloxibutid.
The Phase 2b ASPIRE trial evaluating the safety and efficacy of buloxibutid in IPF patients is currently enrolling.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz